[go: up one dir, main page]

WO1989001495A1 - Agent abaisseur du niveau de cholesterol - Google Patents

Agent abaisseur du niveau de cholesterol Download PDF

Info

Publication number
WO1989001495A1
WO1989001495A1 PCT/JP1988/000781 JP8800781W WO8901495A1 WO 1989001495 A1 WO1989001495 A1 WO 1989001495A1 JP 8800781 W JP8800781 W JP 8800781W WO 8901495 A1 WO8901495 A1 WO 8901495A1
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol
water
protein
molecular weight
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1988/000781
Other languages
English (en)
Japanese (ja)
Inventor
Michihiro Sugano
Minoru Kimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Oil Co Ltd (fka Fuji Oil Holdings Inc)
Original Assignee
Fuji Oil Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Oil Co Ltd filed Critical Fuji Oil Co Ltd
Publication of WO1989001495A1 publication Critical patent/WO1989001495A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof

Definitions

  • the present invention relates to a hypocholesterolemic substance K
  • the present inventors studied the effect of dietary protein poverty on serum cholesterol Ban degree for the purpose of preventing and improving hypercholesterol ⁇ -leukemia by diet.
  • Vegetable proteins such as soybean protein have a lowering effect on serum cholesterol level, and a peptide having a specific molecule S has a cholesterol lowering effect (JP-A-60-11425)
  • JP-A-60-11425 a peptide having a specific molecule S has a cholesterol lowering effect
  • the present inventors have conducted research on the above-mentioned object, and in the course of research on the cholesterol-lowering effect of a seed decomposed product obtained by enzymatic decomposition of S-white, produced by enzymatically decomposing proteins.
  • the finding that the precipitated S fraction (which is water-insoluble but soluble in SDS (SodiuM Dodecyl Sulfate)) has a remarkable cholesterol-lowering effect has led to the present invention.
  • the present invention is based on the water-insoluble S component obtained by removing the water-soluble surface component from the enzymatically degraded product, and is soluble in DS (Sodium dodecyl sulfate) solution, and has a molecular weight of 100 Q after solubilization of the SDS solution.
  • DS Sodium dodecyl sulfate
  • the insoluble fraction that constitutes the cholesterol-degraded product of the present invention » is water-insoluble in an aqueous system * usually insoluble in an aqueous system having a pH of 2 to 8 *
  • the water-insoluble surface constituting the precipitated cholesterol ⁇ TS of the present invention is soluble in a surfactant solution such as SDS (Sodium Dodecyl Sulfate). It is an aqueous composite body,
  • the cholesterol-reduced substance of the present invention is hardly degraded by sulphonic acid remaining after the removal of hydrophilic rush by enzymatic decomposition of protein, and is formed during enzymatic decomposition of aqueous spheres and white or honey white.
  • a water-insoluble surface component (hydrophobic polymer) consisting of different components is encountered.
  • the waterlessness that constitutes the cholesterol ⁇ le 3 ⁇ 4 guest of the present invention is l Approximately 1000-150,000 (preferably 2000-50000) is usually appropriate for molecular tat when solubilized in ⁇ SDS port solution (pHS.9) ⁇ BP, approximately 1000-150,000 (preferably 2000-50,000) (100000) enzymatically decomposed product as it is or forms a polymer to form an S-white enzymatic degradation process.5 Form a water-impervious surface, which is superior in cholesterol lowering action.
  • the cholesterol-depressed product K of the present invention is an aqueous polymer having a good hydrophobic structure, and the ratio of hydrophobic amino acids CTyr, Phe, Val, lie, Leu and Trp) in the amino acid composition is 30% by weight or more. (Preferably 35 weight% above) is appropriate.
  • soy protein itself has a higher cholesterol lowering effect than casein and the like, but the water-insoluble fraction (lower cholesterol substance) obtained by enzymatic degradation of soy protein has Its molecular weight is approximately 1000 to 150,000 (preferably 2000 to 100,000) when solubilized in SD S ⁇ solution (pH 6.9), as determined by high performance liquid chromatography (HPLC).
  • the chromatogram pattern shows a main beak of, for example, about 86000, 7400, and 2500, or has a main peak at about 100,000-2000, which is about 86000, 25000, 7600, and 2900,
  • the ratio of the hydrophobic amino acids (Tyr, Phe, Val ', ⁇ , Leu and Trp) in the amino acid composition is more than 30% by weight (preferably 35% by weight or more).
  • the cholesterol-degraded cholesterol product of the present invention is composed of a water-insoluble fraction, which is not a honey white enzyme-decomposed product having a cholesterol-lowering effect, and is liquid. It can be used as a dry powder for knees. Use in excipients with excipients Too much. Necessary 5 water-insoluble fractions! It is free to contain extra protein, carbohydrates, fiber, vitamins, minerals, their efficacy, etc. Also used as food in seed * foods Since it is derived from natural proteins and has no side effects due to the overdose of intake, it is possible to freely use the amount according to the blood cholesterol level.
  • proteins can be obtained by fractionating a water-insoluble surface obtained by subjecting a protein to an enzymatic decomposition treatment in an aqueous system.
  • the honey white to be used is preferably honey white which has many Hydrophobic regions.
  • ⁇ Hydrophilic region is enzymatically decomposed into aqueous system Bya, which is degraded to low molecular weight and removed as a water port area.
  • Natural white is more preferable than animal white honey, such as casein, because it is rich in the water-insoluble fraction having a cholesterol-lowering effect.
  • the mode of the enzymatic degradation treatment may be any condition under which the desired ice-soluble polymer is obtained.
  • Enzymes used are animal-derived proteolytic enzymes such as pepsin, trypsin, and pancreatin; Known enzymes such as plant-derived proteolytic enzymes such as syn and bu13 melanin, white lipases such as Aspergillus and other white bacteria, and bacterium-derived proteinases such as bacterium, and other microorganism-derived proteases. Can be used,
  • endo-type brothase or the exo-type 13 thase it does not matter whether the endo-type brothase or the exo-type 13 thase is used.
  • a combination of the endo-type protease and the exo-type protease is preferable because an enzymatically insoluble fraction having less bitterness can be obtained.
  • the conditions for the enzymatic digestion treatment may be any as long as the conditions of action of the enzyme (action intensity, action ⁇ , action B / S ratio, action time, action intensity, etc.) are preferable.
  • the conditions under which a greater gag surface area is obtained are more appropriate.
  • the base rinsing degree is higher than the hydrolysis degree, and the pH and the like are slightly shifted from the optimum hydrolysis conditions: For example, in the case of soybean protein, a concentration of about 3 to 205 K is more preferable.
  • separation means known separation means for non-portable substances such as centrifugation, separation, etc. can be used. Les is acceptable *
  • the insoluble fraction referred to in the present invention is a matter of waiting for the search for the insoluble surface. It can contain the amount of water that can be mixed in. * If necessary, a more pure intact component can be obtained by gagging, for example, by repeating the washing.
  • the insoluble surface fraction obtained by dividing the surface may be inactivated by enzyme, neutralized as necessary, sterilized if necessary, and used as it is as cholesterol-lowering 3 ⁇ 4 ⁇ .
  • Known dry explosion methods such as dry smoking and freeze-drying, can be used.
  • the reduced cholesterol of the present invention comprises the non-aggressive fraction obtained as described above as an effective component of reduced cholesterol.
  • the present invention has made it possible to reduce serum cholesterol ⁇ -cholesterol levels which are excellent in the effect of lowering serum cholesterol.
  • HMF cholesterol
  • SPI ⁇ cholesterol diet see Table 1 2
  • mice were given to 5 subgolese 'Dawley' gue-Dawley) male rats (body weight 105-108 g) ( ⁇ -91 group) for 24 days, blood collection and dissection were performed 24 days later, and serum and liver cholesterol transplants were measured. Shown in
  • Table 1 2 ⁇ cholestir-dietary protein poor 20 g
  • the precipitated cholesterol substance (HMF) obtained in the same manner as in Example 1 was dissolved in 1diumSDS (Sodium dodesyl sulfate), and the molecular pattern was changed by HPLC (T SK gel 3000SW, column 7.5 ⁇ X60 cm).
  • the port medium used was a 0,25 M phosphate buffer (pH 5,9) containing SDS, and the fractionation was performed at 0.8 "/ min.
  • Fig. 1 shows the HPLC chromatogram diagram. From this, HMF has a molecular weight of about 1000 to 150,000, including 85,000, 7400, and 2500 as the main beak and a small molecular weight of 120 as a beak. In the range of Glowing,
  • Example 2 In the same manner as in Example 1, a cholesterol made of cocoon made so that the protein shown in Table 14 was adjusted to 20 M as a g element in male Sprasue-Dawley rats (6 rats / 1 group). Diet (See Table 1) * Fed for 14 days, cholesterol level of blood was determined using enzymatic method in the same manner as in Example 1;
  • Difficult soybean protein (“Fujibro NEW-H J Fuji Oil Co., Ltd.”) 100 parts by weight (the following parts) is converted to a 10% aqueous solution of ⁇ 2,0, and 0.5 parts of pepsin (Difco; 1: 10000.Bacto)
  • the enzyme was digested at 37 * 0 for 17:00, and the digestion solution was centrifuged (5000 rp X20 minutes) to obtain a sedimented fraction. About 2 volumes of water was added, and the mixture was shaken and washed. The sedimented fraction obtained by centrifugation at 80 is ripened at 80 for 30 minutes, ripened and deprived of the enzyme.
  • ⁇ Fig. 3 shows the HPLC chromatogram pattern measured in the same manner as in Real Greedy 1.
  • the main beak is the molecule with a maximum molecular weight of about 86000, 25000, 7600, and 2900.
  • the molecular weight was in the range of about 1,000 to 00Q0.
  • Table 1-6 shows the amino acid composition obtained in the same manner as in Jeongseon example 1.
  • the cholesterol-lowering substance (HMF-2) showed remarkable cholesterol-lowering results.
  • No. 113 is a drawing showing the HPLC chromatogram at OD280HB of the cholesterol-falling substance CHMF (F) obtained in Jeongjeong example 1.
  • FIG. 2i is a drawing showing an HPLC chromatogram at OD 280 nm of cholesterol depleted (purified HMF) obtained in Example 1 at OD 280 nm.
  • FIG. 3 is a drawing showing a HPLC chromatogram of cholesterol-lowering substance S (Kasu-made HF-2) obtained in Example 3 at an OD of 280 nm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un agent abaisseur du niveau de cholestérol, qui comprend une fraction hydrosoluble obtenue par extraction d'une fraction hydrosoluble à partir d'une protéine décomposée par voie enzymatique, est soluble dans une solution de dodécyl-sulfate de sodium et son poids moléculaire est compris entre 1000 et 150 000 après sa dissolution dans la solution de dodécyl-sulfate de sodium.
PCT/JP1988/000781 1987-08-07 1988-08-05 Agent abaisseur du niveau de cholesterol Ceased WO1989001495A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP62/198598 1987-08-07
JP19859887 1987-08-07

Publications (1)

Publication Number Publication Date
WO1989001495A1 true WO1989001495A1 (fr) 1989-02-23

Family

ID=16393856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1988/000781 Ceased WO1989001495A1 (fr) 1987-08-07 1988-08-05 Agent abaisseur du niveau de cholesterol

Country Status (1)

Country Link
WO (1) WO1989001495A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000019839A2 (fr) 1998-10-07 2000-04-13 Monsanto Company Produits a forte teneur en beta-conglycinine et leurs utilisations
EP1618791A1 (fr) 1997-04-04 2006-01-25 Monsanto Technology, LLC Produits a forte teneur en beta-conglycinine et leurs utilisations
JP2007126369A (ja) * 2005-11-01 2007-05-24 Q P Corp コレステロール低減化ペプチド、およびこれを含有する血清コレステロール低下材、ならびに血清コレステロール低下作用を有する食品組成物
US7541329B2 (en) 2002-04-18 2009-06-02 Monsanto Technology Llc Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease
JPWO2009123297A1 (ja) * 2008-04-03 2011-07-28 株式会社日立ハイテクノロジーズ 質量分析装置を用いた定量分析方法
WO2025177785A1 (fr) * 2024-02-22 2025-08-28 不二製油グループ本社株式会社 Aliment pour animaux pour chat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5718995A (en) * 1980-07-10 1982-01-30 Terumo Corp Production of low-molecular-weight peptide composition
JPS59175437A (ja) * 1983-03-25 1984-10-04 Teikoku Hormone Mfg Co Ltd 高コレステロ−ル血症改善剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5718995A (en) * 1980-07-10 1982-01-30 Terumo Corp Production of low-molecular-weight peptide composition
JPS59175437A (ja) * 1983-03-25 1984-10-04 Teikoku Hormone Mfg Co Ltd 高コレステロ−ル血症改善剤

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618791A1 (fr) 1997-04-04 2006-01-25 Monsanto Technology, LLC Produits a forte teneur en beta-conglycinine et leurs utilisations
WO2000019839A2 (fr) 1998-10-07 2000-04-13 Monsanto Company Produits a forte teneur en beta-conglycinine et leurs utilisations
US7541329B2 (en) 2002-04-18 2009-06-02 Monsanto Technology Llc Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease
JP2007126369A (ja) * 2005-11-01 2007-05-24 Q P Corp コレステロール低減化ペプチド、およびこれを含有する血清コレステロール低下材、ならびに血清コレステロール低下作用を有する食品組成物
JPWO2009123297A1 (ja) * 2008-04-03 2011-07-28 株式会社日立ハイテクノロジーズ 質量分析装置を用いた定量分析方法
WO2025177785A1 (fr) * 2024-02-22 2025-08-28 不二製油グループ本社株式会社 Aliment pour animaux pour chat

Similar Documents

Publication Publication Date Title
Humiski et al. Physicochemical and bitterness properties of enzymatic pea protein hydrolysates
De la Barca et al. Enzymatic hydrolysis and synthesis of soy protein to improve its amino acid composition and functional properties
US6323319B1 (en) Method of making hydrolyzed collagen type II
Yashiro et al. Hypocholesterolemic effect of soybean protein in rats and mice after peptic digestion
ZA200106787B (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance.
Mookerjee et al. Influence of enzymatic treatments on legume proteins for improved functional and nutritional properties: Expansion of legume protein utilization as food ingredients
Netto et al. Production and characterization of enzymatic hydrolysate from soy protein isolate
WO2012075570A1 (fr) Peptides bioactifs et protéines contenant lesdits peptides bioactifs, leurs utilisations et leurs procédés de réalisation
EP0177605B1 (fr) Composition enzymatique servant de promoteur de la digestion a differents niveaux des voies digestives et procede pour faciliter la digestion
US5387422A (en) Proteolytic fungal enzyme food supplement composition
Kusumah et al. Protein isolation techniques of beans using different methods: A review
EP0065663A1 (fr) Méthode de préparation d'un hydrolysat de protéines à partir du petit-lait
WO1989001495A1 (fr) Agent abaisseur du niveau de cholesterol
KR20070034528A (ko) Ｄｐｐ－ｉｖ 매개 질병의 예방 및／또는 치료용 의약품제조를 위한 단백질 가수분해물의 용도
KIM et al. Recovery of fish bone from hoki (Johnius belengeri) frame using a proteolytic enzyme isolated from mackerel intestine
EP0357776A1 (fr) Hydrolysat d'albumen d' uf
PACHECO et al. Partial characterization of a whey protein concentrate and its enzyme hydrolysates
IL107800A (en) Flavored yeast extracts
Cronlund et al. Effect of microbial rennets on meat protein fractions
Serna et al. Oral administration of Amaranthus hypochondriacus L. hydrolyzed protein isolates to rats with transient hyperglycemia
EP0729710B1 (fr) Composition alimentaire contenant de la laitance
Widmer Pancreatic lipase effectors extracted from soybean meal
Quaglia et al. Proteolysates from slaughter‐house blood
JPH0362382B2 (fr)
James et al. Invitro α-amylase Inhibitory Activity and Antioxidant Profile of Carica Papaya Seed Protein Hydrolysate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US